Annovis Bio Files 8-K
Ticker: ANVS · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, 8-K
TL;DR
Annovis Bio filed an 8-K on Oct 15, 2024. Standard corporate update.
AI Summary
Annovis Bio, Inc. filed an 8-K on October 15, 2024, reporting other events and financial statements. The company, formerly known as QR Pharma, Inc., is incorporated in Delaware and headquartered in Malvern, PA.
Why It Matters
This filing indicates routine corporate reporting, providing updates on company events and financial disclosures to investors.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate events and financial statements, not indicating any immediate material changes or risks.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- QR Pharma, Inc. (company) — Former company name
- October 15, 2024 (date) — Date of report
- Malvern, PA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Annovis Bio, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 15, 2024.
When was Annovis Bio, Inc. previously known by another name?
Annovis Bio, Inc. was formerly known as QR Pharma, Inc., with a date of name change on December 2, 2009.
Where are Annovis Bio, Inc.'s principal executive offices located?
Annovis Bio, Inc.'s principal executive offices are located at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
What is the Commission File Number for Annovis Bio, Inc.?
The Commission File Number for Annovis Bio, Inc. is 001-39202.
What is the fiscal year end for Annovis Bio, Inc.?
The fiscal year end for Annovis Bio, Inc. is December 31.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 9.7 · Accepted 2024-10-15 08:12:41
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
Filing Documents
- tm2426152d2_8k.htm (8-K) — 27KB
- tm2426152d2_ex99-1.htm (EX-99.1) — 8KB
- 0001104659-24-108360.txt ( ) — 209KB
- anvs-20241015.xsd (EX-101.SCH) — 3KB
- anvs-20241015_lab.xml (EX-101.LAB) — 33KB
- anvs-20241015_pre.xml (EX-101.PRE) — 22KB
- tm2426152d2_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: October 15, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer